Syndecan-1 antigen, a promising new target for triple-negative breast cancer immuno-PET and radioimmunotherapy. A preclinical study on MDA-MB-468 xenograft tumors by Rousseau, Caroline et al.
ORIGINAL RESEARCH Open Access
Syndecan-1 antigen, a promising new target for
triple-negative breast cancer immuno-PET and
radioimmunotherapy. A preclinical study on
MDA-MB-468 xenograft tumors
Caroline Rousseau
1,2†, Anne Lise Ruellan
2†, Karine Bernardeau
2, Françoise Kraeber-Bodéré
1,2,3, Sebastien Gouard
2,
Delphine Loussouarn
4, Catherine Saï-Maurel
2, Alain Faivre-Chauvet
2, John Wijdenes
5, Jacques Barbet
2,
Joëlle Gaschet
2, Michel Chérel
1,2 and François Davodeau
2*
Abstract
Background: Overexpression of syndecan-1 (CD138) in breast carcinoma correlates with a poor prognosis and an
aggressive phenotype. The objective of this study was to evaluate the potential of targeting CD138 by immuno-
PET imaging and radioimmunotherapy (RIT) using the antihuman syndecan-1 B-B4 mAb radiolabeled with either
124Io r
131I in nude mice engrafted with the triple-negative MDA-MB-468 breast cancer cell line.
Method: The immunoreactivity of
125I-B-B4 (80%) was determined, and the affinity of
125I-B-B4 and the expression
of CD138 on MDA-MB-468 was measured in vitro by Scatchard analysis. CD138 expression on established tumors
was confirmed by immunohistochemistry. A biodistribution study was performed in mice with subcutaneous MDA-
MB-468 and
125I-B-B4 at 4, 24, 48, 72, and 96 h after injection and compared with an isotype-matched control.
Tumor uptake of B-B4 was evaluated in vivo by immuno-PET imaging using the
124I-B-B4 mAb. The maximum
tolerated dose (MTD) was determined from mice treated with
131I-B-B4 and the RIT efficacy evaluated.
Results:
125I-B-B4 affinity was in the nanomolar range (Kd = 4.39 ± 1.10 nM). CD138 expression on MDA-MB-468
cells was quite low (Bmax = 1.19 × 10
4 ± 9.27 × 10
2 epitopes/cell) but all expressed CD138 in vivo as determined
by immunohistochemistry. The tumor uptake of
125I-B-B4 peaked at 14% injected dose (ID) per gram at 24 h and
was higher than that of the isotype-matched control mAb (5% ID per gram at 24 h). Immuno-PET performed with
124I-B-B4 on tumor-bearing mice confirmed the specificity of B-B4 uptake and its retention within the tumor. The
MTD was reached at 22.2 MBq. All mice treated with RIT (n = 8) as a single treatment at the MTD experienced a
partial (n = 3) or complete (n = 5) response, with three of them remaining tumor-free 95 days after treatment.
Conclusion: These results demonstrate that RIT with
131I-B-B4 could be considered for the treatment of metastatic
triple-negative breast cancer that cannot benefit from hormone therapy or anti-Her2/neu immunotherapy.
Immuno-PET for visualizing CD138-expressing tumors with
124I-B-B4 reinforces the interest of this mAb for
diagnosis and quantitative imaging.
Keywords: breast cancer, syndecan-1, CD138, radioimmunotherapy, immuno-PET, monoclonal antibody
* Correspondence: davodeau@nantes.inserm.fr
† Contributed equally
2Centre de Recherche en Cancérologie de Nantes-Angers, Université de
Nantes, Inserm, U892, Nantes, France
Full list of author information is available at the end of the article
Rousseau et al. EJNMMI Research 2011, 1:20
http://www.ejnmmires.com/content/1/1/20
© 2011 Rousseau et al; licensee Springer. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Background
The expression of syndecan-1 in breast cancer is described
as a poor prognostic factor. However, the potential of
targeting this antigen for immuno-PET or radioimmu-
notherapy has not yet been investigated. Syndecans repre-
sent a four-member family of transmembrane cell-surface
heparan sulfate proteoglycans. Their biological effects on
adhesion, migration, and growth factor signaling are
thought to be mediated by their binding to growth factors,
including FGFs, VEGF, HGF, or ECM molecules, via their
HS chains [1-3]. Syndecan-1, also named CD138, is
expressed by normal epithelial cells but is also transiently
expressed in condensing mesenchyma during embryonic
morphogenesis [4]. The biological functions of syndecan-1
potentially affect several steps in tumor progression and
facilitate metastasis [5]. A prognostic value has been
assigned to changes in syndecan-1 expression in several
cancer types, including breast, colorectal, gastric, pancrea-
tic, prostate, lung, endometrial, and ovarian cancers, as
well as squamous cell carcinoma of the head and neck and
multiple myeloma [6,7]. Syndecan-1 appears particularly
interesting for breast carcinoma radioimmunotherapy
(RIT). The antigen is expressed by potentially aggressive
breast carcinomas, and its expression is tightly associated
with the absence of estrogen receptors (ER) as well as with
a high Ki67 proliferation index [8]. Triple-negative (ER-
negative, progesterone receptor (PR)-negative, HER2/neu
not overexpressed) breast cancer (TNBC) represents
approximately 15% of all breast carcinomas [9]. It gener-
ally occurs in women below the age of 50 years and is
associated with a high risk of distant recurrence and death
during the first 3 to 5 years of follow-up [10]. Cytotoxic
chemotherapy is currently the only treatment available for
TNBC patients, but most of them have chemoresistant
rampant disease with a poor prognosis. However, novel
targeted therapies have the potential to change its natural
course [11]. Monoclonal antibody therapy is one such tar-
geted therapy that may prove beneficial in the manage-
ment of these breast cancer subtypes [9,12].
B-B4 is a murine IgG1 mAb targeting syndecan-1
that was originally developed for multiple myeloma by
Wijdenes and colleagues [13]. The B-B4 mAb has been
shown to have high specificity for syndecan-1, but it is
not cytotoxic for myeloma cells [14]. Subsequently,
one study reported that
131I-labeled B-B4 mAb induced
cellular death in an in vitro multiple myeloma model
[15].
Several radioimmunotherapy clinical trials have been
performed for breast cancer treatment targeting Tag 72,
mucin, CEA, and an adenocarcinoma antigen recognized
by the ChL6 antibody [16-19]. However, objective tumor
responses were obtained with limited toxicity compared
to standard chemotherapy treatment of patients at the
same disease stage. Repeated dosing with radiolabeled
antibody or combination of RIT with other therapeutic
agents might further improve RIT efficacy.
To date, there has been no study investigating the diag-
nostic and therapeutic potential of radiolabeled B-B4
mAb in breast carcinoma, particularly in TNBC cells
such as the MDA-MB-468 cell line that shows many of
the recurrent basal-like molecular abnormalities [20].
The aim of this study was thus to evaluate the biodistri-
bution, toxicity, and RIT efficacy of the radioiodinated
anti-CD138 antibody B-B4 in mice xenografted with the
MDA-MB-468 TNBC cell line.
Methods
Cell line
The human TNBC cell line MDA-MB-468 was obtained
from LGC Promochem (Molsheim, France). The MDA-
MB-468 cell line was cultured in adherent-cell monolayers
in RPMI medium (Gibco BRL, Cergy-Pontoise, France)
supplemented with 10% bovine calf serum (Gibco BRL),
1% glutamine (L-glutamine 200 mM; Gibco BRL), and 1%
antibiotic (penicillin 100 U/ml, streptomycin 100 U/ml;
Gibco BRL). The human myeloma cell line U266 used for
the radiolabeled B-B4 immunoreactivity assay was
obtained from the American Type Culture collection
(Rockville, MD, USA).
Animal model
NMRI-nu (nu/nu) mice over 8 to 10 weeks of age were
grafted subcutaneously in the right flank with 5 × 10
6
MDA-MB-468 cells in 0.1 mL of PBS. The animals were
housed in aseptic conditions. Lugol’s1 %s o l u t i o nw a s
added to drinking water (0.1 mL/L) 2 days before RIT and
then 2 weeks after injecting the radioiodinated reagent.
The mice were injected with radiolabeled mAb 24 days
after MDA-MB-468 engraftment once the tumor volume
had reached a mean volume of 108 ± 55 mm
3.T h em i c e
were housed in our animal core facility according to
ongoing national regulations issued by INSERM and the
French Department of Agriculture. The experiments per-
formed in this study were approved by the local veterinary
services (license number B44.565).
Antibodies and radiolabeling
The reference antibody was the B-B4 anti-CD138 mAb
( I g G 1 ) .T h i sm o u s eI g G 1w a sk i n d l yp r o v i d e db yD i a -
clone (Besançon, France). The 7D4 mAb was used as the
isotype-matched control in the biodistribution studies
[21]. This mAb recognizes the CMH-peptide complex
formed by peptide MAGE3 271-279 and HLA-A2. This
epitope is not expressed on MDA-MB-468 cells. The
antibodies were labeled with
125I (PerkinElmer 16, Ave-
nue du Québec, Courtaboeuf Cedex 1, France) using the
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125I-labeled mAb was purified
on a PD10 column. The B-B4 mAb was also labeled
with
131I (MDS Nordion, Zoning Industriel, Avenue de
L’Espérance, Fleurus, Belgium) using the same iodogen
method. The specific activity ranged from 185 to
200 MBq/mg. Radiolabeling efficiency estimated by
instant thin-layer chromatography (ITLC) was above
95%. The
131I-labeled antibody was not purified further.
Iodine-
124 (IBA molecular, Chemin du cyclotron, 3,
Louvain-la-Neuve, Belgium)
labeling of the B-B4 mAb for immuno-PET imaging was
performed according to a previously described method
[22]. Briefly, 1.7 mg (350 μL) B-B4 in 0.1 M phosphate
buffer pH 7 and 20 μl( 0 . 1m g )o fi o d o g e ni nD M Fw e r e
added to a glass vial containing 230 μL( 2 2 2M B q )o f
Na
124I. After 15 min of incubation under gentle mixing at
room temperature, the radiolabeled antibody was purified
by gel filtration on NAPTM-5 columns (GE Healthcare
UK, Little Chalfont Buckinghamshire, UK). The
124I-B-B4
was recovered in 1.15 ml. The specific activity was
90 mBq/mg, and the radiochemical purity of the purified
radiolabeled antibody was greater than 98% as determined
by ITLC-SG chromatography using trichloroacetic acid at
10% w/v in distilled water as a mobile phase.
Immunoreactivity and affinity
The immunoreactivity of radiolabeled B-B4 was deter-
mined according to the “Lindmo” cell-binding assay using
CD138-positive U266 cells [23]. The number of antigen-
binding sites per MDA-MB-468 cells was determined by
Scatchard analysis as previously described [21]. The bind-
ing data were subjected to nonlinear regression analysis
using a one-site equilibrium binding equation with Prism
software.
Immunohistochemistry
Tumor sections (4 μm) were cut from the tissue microar-
ray blocks and placed on superfrost slides. The immuno-
chemical technique was performed with an automated
immuno-stainer (Labvision, Fremont, CA, USA) using the
strepatavidin-biotin amplification technique (ChemMate
kit, Dako, Glostrup, Denmark) after appropriate antigen
retrieval in EDTA buffer (pH 8) at 95°C. This involved the
application of a specific primary antibody to syndecan-1/
CD138 (clone MI15, 1:100, Dako). A secondary anti-
mouse antibody conjugated to peroxidase was used for
revelation. Peroxidase activity was revealed using 3,3’-dia-
mino-benzidine for 5 min. Sections were counterstained
with Harris hematoxylin for 3 min. Negative controls were
obtained by omitting primary antibodies.
Biodistribution
MDA-MB-468 tumor-bearing mice were given 4 MBq of
125I-labeled B-B4 (5 μg) via the tail vein. The mice were
killed 4, 24, 48, 72, and 96 h after injection (three mice
per time point), the tumor and organs were removed,
weighed, and the radioactivity counted using a gamma
counter. The results were expressed as percent ID per
gram. The same protocol was applied for biodistribution
of the control isotype-matched 7D4 mAb.
PET imaging
Immuno-PET imaging with
124I-labeled B-B4 was per-
formed on six NMRI-nu (nu/nu) mice bearing MDA-MB-
468 xenografts. An activity of 3.3 MBq of
124I-labeled
B-B4 (90 μg) was injected intravenously, and PET images
were acquired 1, 2, 3, 4, and 8 days after injection, with an
Inveon PET scanner (Siemens Medical Solutions, Knox-
ville, TN, USA) under anesthesia (isoflurane-O2). A CT
scan was performed using the docked CT module (Sie-
mens Medical Solutions, Knoxville, TN, USA).
PET imaging with
18FDG was performed on three
NMRI-nu (nu/nu) mice bearing MDA-MB-468 xenografts
receiving an intravenous injection of 6.2 MBq of
18FDG.
PET images were acquired 1 h after injection. PET data
were collected over a period of 20 min (one bed position),
and the 3D sinograms were reconstructed using a 3D
ordered subset expectation maximization followed by a
maximum a posteriori algorithm (3D OSEM-MAP).
Dose escalation and toxicity of
131I-labeled B-B4
The mice were injected i.v. in the lateral tail vein with
escalating activity of
131I-labeled B-B4 mAb. The amount
of B-B4 mAb was adjusted to 120 μg by adding unlabeled
B-B4 antibody and the injected doses were adjusted to a
constant volume of 0.2 ml with sterile PBS. These groups
received 0.0 MBq (n = 4), 11.1 MBq (n =4 ) ,1 4 . 8M B q
(n = 4), 18.5 MBq (n = 4), 22.2 MBq (n = 4), or 25.9 MBq
(n =4 )o f
131I-labeled B-B4 mAb. This assay was repeated
under the same experimental conditions with 25.9 (n =3 )
and 37 MBq (n = 3). The maximum tolerated dose (MTD)
was determined using the data obtained in the two assays
as the dose just below the one at which at least one mouse
died or lost more than 10% of its weight before treatment.
T h em i c ew e r ew e i g h e dw e e k l yf o r9 6d a y s ,a n db l o o d
samples were taken from the inner border of the eye at 0,
14, 28, 40, 55, and 90 days after
131I-labeled B-B4 mAb
injection. Leukocyte and platelet numbers were deter-
mined using a cell counter (Melet-Schloesing Laboratories,
Cergy-Pontoise France).
Radioimmunotherapy
An additional RIT experiment was performed under the
same conditions as those described for the dose escalation
at the MTD (22.2 MBq) (n = 4) and at a lower dose of
14.8 MBq (n = 4) compared to the control group (n = 5).
Tumor volumes were measured with a sliding caliper
twice a week for 96 days measuring tumor length (L),
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lated according to the formula: V = π/6 × L × w × t.
In order to increase statistical power, the results of tumor
growth assessed by this assay were pooled with those of
the corresponding mice groups receiving the same doses
in the dose escalation assay. The effect of unlabeled B-B4
mAb (120 μg) and the
131I-labeled isotype-matched mAb
control was tested in comparison with a PBS control
group in an independent assay.
The parameters used to evaluate the efficacy of each
type of treatment were the minimal relative volume (the
ratio of the smallest measured tumor volume to the initial
tumor volume before treatment) and the event defined as
the growth delay (the time required for the tumor to dou-
ble in size after measurement on the day of treatment).
The mean tumor volume was calculated for each group on
each day of measurement. Tumor responses were categor-
ized as follows: cure (tumor disappeared with no recur-
rence at the end of the study 96 days later), complete
response (CR) (tumor disappeared for at least 7 days but
later re-grew), partial response (PR) (tumor volume
decreased by 50% or more for at least 7 days but then
re-grew).
Statistical analysis
Correlations between dose and degree of toxicity (body
weight loss, platelets, leukocytes) or efficacy (tumor
growth) were made using the nonparametric Spearman’s
test. Groups of interest (radioimmunotherapy doses) were
also compared using the nonparametric ANOVA with
Bonferroni correction. Curves for event-free survival (the
time required for tumors to reach at least twice the initial
volume) were calculated according to the Kaplan-Meier
method and compared using the Log-rank test. All ana-
lyses were two-sided. P values < 0.05 were considered sig-
nificant. Analyses were performed using SAS 9.1 (SAS
Institute, Cary, NC, USA) and Stata 10.0 SE (StataCorp,
College Station, TX, USA). The comparison of the mean
tumor volume curves was performed using a nonpara-
metric test with an on-line software from UCL Institut de
Statistique (Louvain, Belgium) http://www.stat.ucl.ac.be/
ISpersonnel/lecoutre/Tgca/french/help/help.htm.
Results
Immunoreactivity and affinity of radiolabeled B-B4 mAb
CD138 expression was studied upon equilibrium binding
of the specific B-B4 antibody to the human breast cancer
MDA-MB-468 cell line. The expression of CD138 on this
cell line was rather low; only 1.19 × 10
4 ±9 . 2 7×1 0
2
CD138 sites per cell were detected with saturating
amounts of B-B4 mAb (Figure 1A). This result is consis-
tent with previous work indicating that MDA-MB-468 is
among the lowest syndecan-expressing breast cancer cell
lines [24]. The affinity (dissociation constant) of B-B4
mAb was 4.39 ± 1.10 nM. The immunoreactivity assessed
using the method described by Lindmo [23] (Figure 1B)
was close to 80%, showing that the labeling did not modify
the binding of B-B4 mAb to the CD138 antigen. For
Figure 1 Characterization of the B-B4 mAb. (A) The affinity of B-B4 mAb and the number of antigenic sites on MDA-MB-468 breast cancer
cells were evaluated by an equilibrium-binding assay with
125I-labeled B-B4 mAb. The nonspecific binding of
125I-labeled B-B4 mAb was
evaluated with a tenfold excess of unlabeled B-B4 mAb at three concentrations of
125I-labeled B-B4 mAb and subtracted from binding data. The
mean results of a triplicate assay are represented. The Bmax corresponding to the number of antigenic sites on MDA-MB-468 cells, and the Kd of
125I-labeled B-B4 were determined by nonlinear regression using a one-binding site equation. (B) The immunoreactivity of
125I-labeled B-B4 mAb
was estimated by measuring the binding of a constant concentration of
125I-labeled B-B4 mAb to increasing numbers of U266 multiple myeloma
cells that strongly expressed the CD138 antigen. This is a double-inverse plot of a triplicate assay. The fraction of immunoreactive
125I-labeled B-
B4 (R) was determined as the inverse of the ordinate at the origin of the abscissa according to the Lindmo method [23].
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on the multiple myeloma cell line U266 that expresses at
least ten times more CD138 antigen than MDA-MB-468
cells.
Immunohistochemistry
Syndecan-1 expression was further investigated by immu-
nohistochemistry on xenograft tumors in order to validate
the preclinical model for CD138 targeting. The lack of
estrogen or progesterone receptor and Her2/neu expres-
sion on the MDA-MB-468 cell line was consistent with
the capacity of this cell line to form tumors in nude mice
without additional hormone treatment. Figure 2 presents
micrographs of an MDA-MB-468 xenograft with hema-
toxylin-eosin staining (panel A) and CD138 immunostain-
ing (panel B). The trabeculae of carcinoma cells were
observed with high nuclear pleomorphism, high mitotic
activity, and a central necrosis. Despite the relatively low
expression of CD138 on cultured MDA-MB-468 cells,
intense membrane immunostaining of carcinoma cells
from tumor xenografts was visualized by CD138 immu-
nostaining with the B-B4 mAb.
Biodistribution of
125I-labeled B-B4 mAb
In mice injected with
125I-labeled B-B4 mAb, maximum
tumor uptake was reached at 24 h (13.8% ± 1.8% ID per
gram) and was maintained over time with a tumor uptake
of 8.4% ± 1.9% ID per gram at 96 h (Figure 3A). In normal
tissues, the maximum accumulation was observed at 4 h
but rapidly decreased with kinetics similar to those for
blood (Figure 3C). A higher level of
125I-labeled B-B4
mAb was observed in the more vascularized organs such
as the heart and lungs, in keeping with their higher blood
content. The level of
125I-labeled B-B4 mAb in the blood
reflected the serum stability of radiolabeled B-B4 mAb.
We further investigated the specificity of B-B4 mAb
tumor uptake by comparing it with the biodistribution of
an isotype-matched control antibody. To this end, we used
the 7D4 IgG1 antibody developed in our laboratory, which
does not bind to MDA-MB-468 cells. Tumor uptake mea-
sured with the nonspecific 7D4 mAb was subtracted from
that detected with the B-B4 mAb in the same assay. The
results presented in Figure 3B clearly show that all organs
except the tumor displayed an identical B-B4 and 7D4
mAb uptake, with differences that did not exceed 1% ID
per gram. Conversely, a clear and specific binding of
125I-labeled B-B4 mAb was observed in the tumor. This
specific
125I-labeled B-B4 mAb uptake increased rapidly
o nt h ef i r s td a yp o s ti n j e c t i o na n da tal o w e rr a t eu pt o
72 h thereafter (Figure 3D). The tumor uptake was long
lasting since 7 days after injection, it reached at least 80%
of the maximum measured at 72 h (data not shown).
Nevertheless, B-B4 tumor uptake was relatively low as
compared to other tumor-specific antibodies. Conse-
quently, in this MDA-MB-468 tumor model, the tumor/
blood ratio is almost 1:1, as compared to 2:1 in other mod-
els. These observations can be explained by the low
CD138 expression by this breast cancer cell line, together
with the central necrosis in the tumors at the time of the
biodistribution study.
Immuno-PET imaging
The availability of isotopes of the same element, such as
124Ia n d
131Io r
86Ya n d
90Y, offers the possibility to
image tumors by immuno-PET with the antibody used
for therapy with identical labeling technology and, there-
fore, the same pharmacokinetics. This should afford
more accuracy in dosimetry calculations before therapy
and in providing information on tumor antigen expres-
sion complementary to metabolic
18FDG-PET imaging.
We thus used the B-B4 mAb labeled with
124If o r
immuno-PET imaging in mice engrafted with MDA-
MB-468 cells. Imaging was performed on days 1, 3, and
8 for mice injected with 3.5 MBq
124I-labeled B-B4 mAb
Figure 2 Immunohistochemistry of a MDA-MB-468 breast
tumor xenograft. The expression of CD138 in MDA-MB-468
xenografts was assessed by immunohistochemistry. (A) Original
magnification ×400 for hematoxylin-eosin staining. (B) Original
magnification ×400 for CD138 immunostaining.
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18FDG injection. Tumor imaging with
124I-
labeled B-B4 was as informative as
18FDG for tumor
visualization, even 1 day after antibody injection (Figure
4). Immuno-PET images recapitulated the results of bio-
distribution at all times, with a clear tumor imaging at
day 1 together with an intense activity in the heart and
blood vessels. At day 3, when antibody tumor uptake
had reached its maximum, the staining was intense and
comparable with that of the heart, which is in accor-
dance with the equal uptake of the antibody in the
blood and tumor observed at 72 h in the biodistribution
study. Finally, at day 8, the persistence of the labeled
antibody within the tumor, together with the decline in
blood content, led to a well-contrasted image of the
tumor with little signal remaining in normal tissues.
This imaging assay validates the feasibility of syndecan-1
targeting for immuno-PET imaging with the B-B4 mAb.
RIT toxicity and MTD
We performed a dose escalation study from 11.1 to
37 MBq with a 3.7-MBq increment of
131I-labeled B-B4
mAb. Hematological toxicity was assessed by platelet and
leukocyte numeration (Figure 5). For platelets, the nadir
was observed at day 14. A dose-dependent drop in plate-
let count was observed from 11.1 to 25.9 MBq reaching
respectively 67.4% and 38.6% of the platelet number
before treatment (0.56 × 10
6/mm
3 vs. 1.45 × 10
6/mm
3
and 0.99 × 10
6/mm
3 vs. 1.47 × 10
6/mm
3, respectively).
Am o r ed r a m a t i cd r o pw a so b s e r v e da t3 7M B qw h e r e
the platelet count at day14 decreased to 15% of the pre-
treatment value, arguing for an acute hematological toxi-
city at this injected activity. The platelet count reverted
to normal by day 40 at injected activities ranging from
11.1 to 25.9 MBq. The evolution of leukocyte count over
time was similar to that of platelets, with a nadir at
Figure 3 Biodistribution of
125I-labeled B-B4 mAb. (A) The biodistribution of
125I-labeled B-B4 mAb was estimated in nude mice engrafted
with the MDA-MB-468 breast cancer cell line. The results are expressed as mean values ±95% confident intervals of the percentage of injected
dose per gram (%ID/g) in the considered organ or tissue from three triplicate assays. (B) This panel shows the specific binding of the B-B4
antibody calculated by subtracting the %ID/g of the
125I-labeled 7D4 isotype-matched control antibody to that of
125I-labeled B-B4 measured in
a triplicate assay under the same experimental conditions for both antibodies. (C) The %ID/g of
125I-labeled B-B4 mAb obtained from
biodistribution studies at different time points are plotted versus time in order to visualize the kinetics of activity uptake in different tissues. (D)
The kinetics of 7D4 and B-B4 distribution in the blood and tumors are shown in the same graph to demonstrate the identical blood
pharmacokinetics of both antibodies and the specific uptake of BB4 in the tumor. The difference between the uptake of the two antibodies in
the tumor is not significant at 4 h but is clearly significant at 24, 48, and 72 h (p < 0.001 determined by a two-way ANOVA test).
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ging from 14.8 to 25.9 MBq decreased respectively to
19.7% and 7.9% of the pretreatment value (1,000 vs.
5,075/mm
3 and 460 vs. 5,847/mm
3, respectively). An
injected activity of 11.1 MBq was less toxic with a leuko-
cyte count of 47.0% at day 14 and a rapid recovery of
normal counts as early as 26 days after treatment. With
the exception of the 37 MBq group in which all mice
died, a progressive recovery in leukocyte number
occurred after the nadir and a normal count was reached
70 days after injection of
131I-labeled B-B4 mAb. In
summary, activities ranging from 11.1 to 25.9 MBq
induced a dose-dependent hematological toxicity that
spontaneously resolved in 40 days for platelets and
70 days for leukocytes. An injected activity of 37 MBq
was clearly toxic.
The monitoring of animal survival and weight con-
firmed the mild toxicity of injected activities ranging
from 11.1 to 22.2 MBq with no weight loss above 10%
and no mortality during the follow-up period. Conver-
sely, higher doses were toxic, with weight loss above
10% and death of all mice within 3 weeks of injection of
Figure 4 Immuno-PET imaging with
124I-labeled B-B4 mAb. PET image obtained 1 h after injection of 6 MBq
18F-FDG and at days 1, 3, and 8
after injection of 3.5 MBq of
124I-labeled B-B4 mAb.
Figure 5 Figure 5. Hematological toxicity of
131I-labeled B-B4 mAb. Hematological toxicity was estimated by counting the leukocytes (A)
and platelets (B) after treatment with increasing doses of
131I-labeled B-B4 mAb. All mice treated with 37 MBq died before day 14.
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131I-labeled B-B4 mAb. In the 25.9-MBq group,
one mouse out of seven died during the follow-up and
two mice lost more than 10% of their initial weight.
Therefore, we defined the 22.2-MBq injected activity of
131I-labeled B-B4 mAb as the MTD.
RIT efficacy
The RIT assay was performed 24 days after engraftment of
five million MDA-MB-468 cells when well-established
tumors of a mean volume of 108 ± 55 mm
3 were obtained.
The mice were treated with 22.2 or 14.8 MBq with a con-
stant molar amount of B-B4. A clear tumor response was
observed for the group of mice treated with 14.8 and
22.2 MBq of
131I-labeled B-B4 mAb, as compared to the
control group (Figure 6A). Unlabeled B-B4 had no effect
on tumor growth when used at the same molar dose as
the
131I-labeled B-B4 mAb in the RIT assay. Equivalent
activities of a nonspecific an t i b o d yw e r ea l s ot e s t e db u t
without a tumor response (Figure 6B). Despite individual
variations in tumor growth within each group, the statisti-
cal analysis revealed a very significant difference in mean
tumor volumes between control and 22.2-MBq-treated
animals on the one hand and between 14.8- and 22.2-
MBq-treated animals on the other hand (p < 0.0001).
A significant difference between control and 14.8-MBq-
treated animals (p = 0.028) was also observed, confirming
the efficacy of
131I-labeled B-B4 mAb RIT (Figure 6A).
In the group of eight mice that received 22.2 MBq
131I-labeled B-B4 mAb, five achieved a CR and three a PR
(duration of 48 ± 32 days), and three mice were cured at
the end of the assay. For the group of mice injected with
14.8 MBq of
131I-labeled B-B4 mAb, three out of eight
treated mice achieved PR (duration of 31 ± 5 days), and
all the mice had a tumor volume reduction within the
20 days following treatment, whereas tumor growth was
continuous in the control group. We further analyzed the
Figure 6 Radioimmuntherapy assay. (A) Tumor size variations in individual nude mice engrafted with the MDA-MB-468 cell line after
treatment. Mice treated with 14.8 (n = 8) or 22.2 MBq (n = 8) of
131I-labeled B-B4 mAb can be compared with control mice (n = 9) that
received unlabeled B-B4 mAb. The mean tumor volume of each group of mice is represented. The curves are very significantly different for the
control versus 22.2 MBq (p < 0.0001) and the 14.8 MBq versus the 22.2 MBq groups (p < 0.0001) and significantly different for the control versus
the 14.8 MBq groups (p = 0.028). (B) The effect of the unlabeled B-B4 mAb (n=5) and PBS (n=5) were tested in an independent experiment (left
panel). The effect of RIT with 131I-labeled control isotype mAb (14.8, n=3 and 25.9 MBq, n=4) and 131I-B-B4 (14.8, n=4 and 22.2 MBq, n=4) and
control PBS (n=4) were compared (right panel). Results are expressed as fold-increase in tumor volume compared to day 0. This figure
summarizes the results of two independent assays performed under the same conditions. (C) The time required for tumors to double in size in
groups given 14.8 and 22.2 MBq
131I-labeled B-B4 mAb compared with the control group..
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Page 8 of 11tumor response by comparing the growth delay (the time
required for the tumor to double in size after measure-
ment on the day of treatment) in the control, 14.8 MBq,
and 22.2 MBq
131I-labeled B-B4 mAb-treated animals
(Figure 6C). A statistically significant difference was found
when groups were compared to each other, confirming
the dose-dependent efficacy of
131I-labeled B-B4 mAb RIT
treatment. The mean growth delays were 28 ± 13 days and
58 ± 17 days for the control group and the 14.8 MBq
groups, respectively; whereas, in the group of eight mice
treated with the 22.2 MBq dose, only three had a bigger
tumor at the end of the follow-up than at the date of injec-
tion. Despite the low tumor/blood ratio, this assay demon-
strated that targeting low CD138-expressing triple-
negative breast cancer cells with
131I-labeled B-B4 mAb
affords a very encouraging tumor response with only tran-
sient toxicity.
Discussion
The MDA-MB-468 cancer cell line is representative of
triple-negative breast cancer that has a poor prognosis.
As such, it is often used as xenografts in nude mice to
test new drugs and therapeutic strategies against breast
cancer. Recent studies with a variety of drugs and combi-
nation therapies, including antimitotic agents and small
molecules inhibiting several signaling pathways resulted
in significant tumor growth control but in no real break-
through. The same model was previously used for RIT
studies of the RS7 antibody or its humanized equivalent
hRS7 [25,26], with reported remission rates varying
between 9% and 70%. The latter antibody recognizes a
pancarcinoma antigen also known as EGP-1 or Trop2. In
this paper, we show that when radiolabeled with appro-
priate iodine isotopes, the anti-CD138 (syndecan-1) anti-
body B-B4 shows favorable biodistribution, imaging
capability, and antitumor properties in the same MDA-
MB-468 xenograft model, with three PR, five CR, and
three cured animals in a group of eight with established
tumors, despite a relatively low expression of the target
antigen. In fact, the equilibrium binding assay showed
that the number of antigenic sites was as low as 1.2 × 10
4
per cell, which is consistent with previous reports [27,24].
This low level of CD138 expression explains the relatively
low tumor/blood ratio found in the biodistribution analy-
sis of the B-B4 antibody and the relatively high injected
activity (22.2 MBq) required to cure mice from their
tumor in the RIT assay. The treatment efficiency is prob-
ably explained by the long residence time of activity in
the tumor. This was illustrated by immuno-PET imaging
where the best tumor images were obtained 8 days after
124I-labeled B-B4 injection. No adverse effects were
observed at the MTD defined as 22.2 MBq. Other groups
targeted breast cancer xenografts using whole antibodies
radiolabeled with
131I and have reported MTD ranging
from 7.4 MBq for the
131I-labeled anti-Lewis Y hu3S193
antibody [28] to 44.4 MBq for the
131I-labeled anti-
MUC-1 Mc5 antibody [29]. Interestingly, antibodies tar-
geting the same antigen displayed a very different MTD.
Behr and colleagues targeted ACE with the mouse IgG1
mAbs MN-14 and F023C5 and observed an equivalent
RIT efficacy on GW-39 colon carcinoma, with an MTD
of 9.62 and 22.2 MBq, respectively [30-32]. The 22.2
activity that we determined as the MTD for
131I-labeled
B-B4 mAb is in the range of these previously described
MTDs.
The choice of the radionuclide for imaging and therapy
could influence the efficiency of these approaches.
131I
presents some advantages, notably the possibility of ima-
ging and dosimetry and a low activity uptake in the liver.
131I-labeled antibodies are successfully used in consolida-
tion treatment of hepatic metastases of colon cancer after
surgical removal of macroscopic lesions [33] or in the
treatment of B cell lymphoma [34-36]. However, mAb
labeled with iodine isotopes using the conventional chlora-
mine-T method could result in a loss of efficacy due to the
rapid escape of iodotyrosine resulting from the catabolism
of the radioiodinated antibody within the lysosomal com-
partment, especially in the case of internalizing mAb. Sev-
eral groups have reported that CD138 is internalized.
However, the internalization mechanism has been
described as clathrin-independent. Internalization has
been shown to be fast and to involve a multistep process:
ligand binding, clustering, energy-independent lateral
movement into detergent-insoluble membrane rafts, and
recruitment of actin and tyrosine kinases [37,38]. This
mechanism has been studied by several groups using
iodine-labeled ligands of CD138 or of a CD138-FcR fusion
protein. Fast degradation of the ligands, like that usually
observed for proteins endocytosed via clathrin-coated pits,
does not seem to occur after CD138 internalization. In
addition, our biodistribution data showed little decrease in
tumor activity accumulation up to 96 h, while the circulat-
ing antibody concentration decreased at least threefold. In
the present study of xenograft MDA MB, 468 PET ima-
ging with
124I-labeled B-B4 confirmed the accessibility of
the CD138 antigen and showed a good stability of tumor
activity up to 8 days post injection. Thus, deiodination of
the radiolabeled antibody seemed to be limited and does
not preclude the possibility of performing radioimmu-
notherapy with
131I-B-B4. Although further studies are
needed using a residualizing agent such as that described
by Goldenberg and co-workers [26] or of radioactive
metals such as lutetium-177 or yttrium-90 to increase the
efficiency of RIT, here we show the potential of targeting
CD138 for the treatment of breast cancer in the mouse
model with a significant response rate despite the low
number of antigen copies expressed by the triple-negative
MDA-MB-468 cells.
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is associated with an aggressive breast cancer phenotype.
CD138 is expressed by about 75% of ER-negative forms of
breast cancer [39], and it is associated with a high histolo-
g i c a lg r a d e ,K i6 7i n d e x ,t u m o rs i z e ,a n dl y m p hn o d e
involvement [8,40]. RIT targeting CD138 could thus be
very useful in the treatment of triple-negative breast can-
cer that is not eligible for hormone therapy or immu-
notherapy targeting Her2/neu. TNBC accounts for 10% to
17% of all breast carcinomas and among two thirds of
TNBC patients express CD138 on their primary tumor.
TNBC are chemosensitive, but TNBC patients with resi-
dual disease postchemotherapy have a poor outcome with
an increased likelihood of distant recurrence [41]. Target-
ing tumor cells by RIT with
131I-labeled B-B4 mAb could
offer the possibility to achieve responses on chemoresis-
tant cancer cells for patients who relapse after intensive
chemotherapy because ionizing radiations act differently
on cancer cells. When considering breast cancer irrespec-
tive of the ER or PgR expression status, CD138 expression
is associated with the worst prognostic marker Her2/neu.
Barbareschi and colleagues reported on an additive
adverse effect when both Her2/neu and CD138 were over-
expressed [40]. Patients suffering from this kind of cancer
can be treated by immunotherapy with herceptin asso-
ciated to radioimmunotherapy with
131I-labeled B-B4
mAb in order to obtain a synergy between the two thera-
peutic approaches when used in association or as an addi-
tional line of treatment for patients who relapse.
It is generally accepted that RIT is more adapted to the
systemic treatment of small tumors like metastasis. The
expression of CD138 on primary breast tumors and in the
corresponding invaded lymph node has been evaluated.
The level of expression in invaded lymph nodes is at least
equal to that of the primary tumor [24]. The shift of
CD138 expression from epithelial cancer cells to fibro-
blasts of the stroma should not preclude RIT efficacy as
long as the overall level of CD138 expression in the tumor
ensures sufficient uptake. Indeed, the millimeter range of
beta particles enables the irradiation of cells surrounding
tumor epithelial cells via the cross-fire effect [42,43].
Conclusion
RIT targeting CD138 is relevant for the treatment of tri-
ple-negative breast cancer and could be applied to patients
who relapse after a first-line treatment. The possibility of
visualizing tumors by immuno-PET and to perform quan-
titative imaging prior to therapy provides the advantage of
being able to assess CD138 expression in order to con-
clude on the feasibility of RIT [18] for each patient.
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